Physician profile
Allison H Mabus
NPI 1578727970
$1,214.80
in general payments reported to CMS, 2019-2025
24 companies · $81.10 in 2025
The $81.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $16.68 · 2022: $267 · 2023: $233 · 2024: $151 · 2025: $81.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.11 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $130.03 | 2023-2024 | Corevalve Evolut R, Venaseal |
| Abbvie INC. | $105.08 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.79 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.28 | 2019-2023 | Breztri |
| Boston Scientific Corporation | $59.71 | 2022 | |
| Lilly USA, LLC | $47.97 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $39.66 | 2019-2022 | |
| Exact Sciences Corporation | $37.77 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $36.41 | 2023 | Myrbetriq |
| Pfizer INC. | $31.79 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $30.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.56 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.72 | 2023 | Quviviq |
| Abbott Laboratories | $19.22 | 2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.13 | 2019 | |
| Glaxosmithkline, LLC. | $18.82 | 2025 | Arexvy, Fluarix Quadrivalent, Shingrix |
| Insmed, INC. | $16.24 | 2024 | Arikayce |
| Merck Sharp & Dohme LLC | $14.17 | 2019 | |
| Corium, LLC | $13.44 | 2022 | |
| Shire North American Group INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Mabus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.